Earnings Presentation for the Quarter and Year ended March 31, 2026
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Advanced Enzyme Technologies reported strong Q4 FY26 results with revenue of ₹2,034 million (up 22% YoY), EBITDA of ₹632 million (up 39% YoY), and PAT of ₹453 million (up 69% YoY). For the full year FY26, revenue grew 17% to ₹7,458 million, EBITDA rose 18% to ₹2,291 million, and PAT increased 30% to ₹1,736 million. EBITDA margin expanded to 31% and PAT margin to 23% in FY26. Human Nutrition segment contributed 63% of Q4 revenue and grew 24% YoY. India operations showed exceptional growth of 51% YoY, while Americas declined 11%. The company outlined focus areas including new probiotic product launches, bio-catalysis expansion for API manufacturers, and baking solutions expansion in Europe.
Strong margin expansion and robust profit growth indicate operational efficiency gains. The company appears well-positioned in enzyme and probiotics markets with diversified segments. India growth significantly outpacing other geographies may signal shifting market dynamics.